Edgewise Therapeutics, Inc. — Director's Dealing 2021

Nov 12, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edgewise Therapeutics, Inc. (EWTX)
CIK: 0001710072
Period of Report: 2021-11-09

Reporting Person: Russell Alan J (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-09	Common Stock	S	16864.00	$19.9404	Disposed	53355.00	Direct
2021-11-09	Common Stock	S	12712.00	$20.2982	Disposed	40643.00	Direct
2021-11-10	Common Stock	S	11746.00	$19.7043	Disposed	28897.00	Direct
2021-11-10	Common Stock	S	580.00	$20.2122	Disposed	28317.00	Direct
2021-11-11	Common Stock	S	15595.00	$19.8168	Disposed	12722.00	Direct
2021-11-11	Common Stock	S	3681.00	$20.428	Disposed	9041.00	Direct
2021-11-12	Common Stock	S	8562.00	$19.5134	Disposed	479.00	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on June 17, 2021.

F2: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $19.17 to $20.165, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $20.17 to $20.58, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $19.095 to $20.05, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $20.16 to $20.35, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F6: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $19.29 to $20.285, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $20.29 to $20.82, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F8: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $19.01 to $19.89, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.